Company Overview and News

 
Elanco Animal Health prices IPO above expected range

49m marketwatch
Elanco Animal Health Inc. ELAN, +0.00% priced shares for its initial public offering above the estimated range late Wednesday. The animal drug company, which is being spun off from Eli Lilly & Co. LLY, -1.07% priced shares at $24 a piece. Earlier in the month, Elanco had estimated shares in the $20 to $23 range. Under current pricing, Elanco hopes to raise up to $1.74 billion on an offering of 62.9 million shares with an added 9.
DTK MS

6
S&P 500, Dow up as rising treasury yields boost banks

1h channelnewsasia
U.S. stock markets headed for a flat open on Wednesday, holding just off three-week highs after brushing aside the latest blows in Washington and Beijing's trade war.
FB GOOGL AAPL GOOG MS

6
S&P 500, Dow up as rising treasury yields boost banks

1h reuters
NEW YORK (Reuters) - The S&P 500 and the Dow Jones industrial average rose on Wednesday, with the Dow hitting its highest closing level since late January as rising Treasury yields boosted the financial sector and trade worries subsided.
FB GOOGL AAPL GOOG MS

60
6 Big Bank Stocks Leading the Breakout

2h investorplace
The Dow Jones Industrial Average is pushing to a new record high on Wednesday, lifting toward the 26,500 level, as the financial sector gets a huge lift from rising long-term interest rates. This is the offset from the weakness hitting the bond market, with the 10-year Treasury yield pushing well past the 3% threshold to move near levels not seen since 2011.
BAC USB GS C JPM MS

3
GWPH Stock Surges on Reclassification of Epidiolex

2h investorplace
GW Pharmaceuticals (NASDAQ:GWPH) shares were surging on Wednesday as the U.S. Drug and Enforcement Administration (DEA) has plans to reclassify one of its medications.
GWPH MS GWP

2
Stuart Varney of Fox Business News and the Lessons of the 2008 Financial Crisis

3h investorplace
Fox Business News Anchor Stuart Varney was reporting from Wall Street during the thick of the 2008 financial crisis. As the investing world marks 10 years since those events unfolded, InvestorPlace asked him about his memories of that time and to provide his take on what investors should have learned from those dark days.
MS AIG

6
US STOCKS-Financials boost S&P 500, Dow; tech drags on Nasdaq

3h reuters
(For a live blog on the U.S. stock market, click or type LIVE/ in an Eikon news window.)
FB GOOGL AAPL GOOG MS

 
Banks lift S&P, Dow; Nasdaq weighed by Microsoft

5h reuters
(Reuters) - The S&P 500 and the Dow Jones Industrials Average rose on Wednesday, helped by upbeat housing data and a gain for bank stocks driven by rising Treasury yields, while the tech-heavy Nasdaq was weighed by a drop in Microsoft.
CPRT MS

12
Morgan Stanley Sees Huge Upside for Oil Services in 2019 and 2020

5h 247wallst
It has been hard for investors to make some of the same gains in the oil and gas segment since oil prices have recovered handily. That may be about to change, or at least that is the take of Morgan Stanley. The firm issued a series of major upside calls for its clients looking to profit within oil and gas.
WFCNP HAL MS RIG WFC SLB BHGE NBR DO DRQ BHI TRI SCL SLB SGAZF

40
3 Reasons Alphabet Stock Is a Must-Buy on Recent Pullback

6h investorplace
I wouldn’t recommend ignoring Alphabet (NASDAQ:GOOG, NASDAQ:GOOGL) for too long. This is a high-quality company with strong growth, immense profitability and plenty of potential going forward. Despite strong earnings in late July, Alphabet stock has had trouble moving higher.
AMZN GOOGL AAPL MSFT GOOG MS

1
Microsoft: Disappointing Dividend Raise?

6h seekingalpha
After the bell on Monday, technology giant Microsoft (MSFT) announced that the quarterly dividend had been raised. Shareholders are going to receive more income now thanks to a 4 cent per quarter boost in the payout to $0.46 per share. While investors always appreciate the extra cash, there's a case to be made that Microsoft did not go far enough this year.
MSFT MS

 
Anaplan Files Plans For U.S. IPO

6h seekingalpha
Anaplan (PLAN) intends to raise gross proceeds of $100 million from a U.S. IPO, according to an S-1 registration statement.
MS RHT

 
Babcock International Group PLC (BCKIF) Trading Update Conference (Transcript)

7h seekingalpha
Good morning. First of all, thank you for joining the call this morning, following the issue of updated trading statement. I’m joined this morning with Franco Martinelli, our Group Financial Director. And after I make a few opening remarks, we’ll be happy to take the questions.
BCKIF MS BCKIY

 
X Financial's stock rockets on its public debut, and keeps rising

7h marketwatch
Shares of X Financial XYF, -9.53% soared in their public debut, with the first trade at $15 at 10:35 a.m. ET, or 58% above the initial public offering price of $9.50. The stock has rallied further since, and was recently up 99% at $18.93. The IPO of American Depositary Shares of the China-based tech-driven personal finance company priced overnight at $9.50, compared with the expected range of $9.00 to $11.
DB MS

4
Goldman shares rise as rivals line up to take stakes in bank's 'Simon' investing app

7h cnbc
Goldman Sachs shares jumped 2 percent after word it has lined up rival banks to take stakes in its three-year-old app devoted to selling complex investment products.
WFCNP HSB MS HSBC HBCYF WFC PRU PFK HCS 0005 PRH HSEA HSEB PJH

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 61761J406